Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

e voluntarily terminated our phase 3 studies of clevudine after we became aware of a number of spontaneous Serious Adverse Event reports and Events of Special Interest in patients receiving clevudine as prescribed therapy for HBV in South Korea, where the drug is marketed by Bukwang under the trade name Levovir, and in Hong Kong, where clinical studies were being conducted under the sponsorship of Bukwang. Given the number and severity of cases observed in South Korea and Hong Kong, we determined it was in the best interest of patients to voluntarily terminate our registration studies. All patients have now completed the follow-up period and we anticipate concluding activities by the end of the quarter ending December 31, 2009.

"Pharmasset has had a tremendous year on all fronts," said Schaefer Price, Pharmasset's President and CEO. "In collaboration with Roche, we are advancing our first in class nucleoside analog, RG7128, through a phase 2b trial and also exploring the paradigm-changing model of an all oral (interferon sparing) regimen for HCV. We reported best in class results with our second generation nucleotide analog inhibitor, PSI-7851 and anticipate starting phase 2a trials in the first quarter 2010. We believe nucleosides/tides will have an advantage in the marketplace when used with the current standard of care, due to their high RVR rates, pan-genotype activity and high barrier to resistance. In the future, as we move towards oral combinations, we believe our nucleoside/tides have the potential to be used in combination with one another and with other classes of direct acting antivirals."

Financial Results

For the fiscal year ended September 30, 2009 Pharmasset reported revenues of $13.3 million, compared with revenues of $1.9 million for the fiscal year 2008. The receipt of a $10.0 million milestone from Roche for the initiation of the phase 2b study with RG7128 led to higher reported revenues in the fiscal year
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. today announced that the U.S. Food and Drug ... (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment ... by any diagnosed conditions of the uterus (womb), in ... With this approval, Natazia is the first and only ...
... March 14, 2012  Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced the schedule of ... American College of Cardiology (ACC) 61th Scientific Session, ... Monday, March 26, 2012 Time: 10:00 AM -12:00 PM ...
Cached Medicine Technology:U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 2U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 3U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 4Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting 2
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... researchers will lead a $10.25 million effort to study ... need for dialysis. The five-year project supports research ... that, though rare, generates an enormous individual and societal ... to nearly 12 percent of cases of kidney failure, ...
... , , , ... by wearing a purple LFA wristband until there is an FDA-approved medication ... It,s been 50 years since the U.S. Food and Drug Administration (FDA) ... President! To highlight the need for safer, more tolerable, and effective medications, ...
... NEW YORK, Sept. 22 The Global Network ... partnership with the Miss Universe Organization aimed at educating millions ... control and eliminate neglected tropical diseases across the region. ... time in their home countries participating in education and mass ...
... , , SAN MARCOS, Calif., ... NAII ), a leading formulator, manufacturer and marketer of customized nutritional ... per diluted share on net sales from continuing operations of $73.9 ... fiscal 2009 results include a net loss from discontinued operations of ...
... , , NEW YORK, Sept. 22 ... of specialty insurance and insurance-related products and services, will release 2009 third ... The news release will be available on Assurant,s Web site at ... broadcast its 2009 third quarter conference call at 9:00 a.m. ET on ...
... ELM GROVE, Wis., Sept. 22 A free ... Factor in HAI , is being sponsored by Compirion Healthcare Solutions, ... Wisconsin. Dates and times, along with registration information, can be found ... webinar are the main causes of non-compliance with hospital hand-washing ...
Cached Medicine News:Health News:Kidney advocates launch $10.25 million effort to examine cause of kidney failure 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2Health News:Miss Universe Organization, Global Network for Neglected Tropical Diseases Join Forces to Eliminate Neglected Tropical Diseases in the Americas 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 3Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 4Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 5Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 6Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 7Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 8Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 3